183490 — Enzychem Lifesciences Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro Cap
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot
Brief: Enzychem Files For FDA Breakthrough Therapy Designation For EC-18 For The Treatment Of Chemoradiation-Induced Oral Mucositis
Brief: Enzychem Lifesciences Announces Positive Results For Phase 2 U.S. Study Of EC-18 In Chemoradiation-Induced Oral Mucositis
Brief: Enzychem Lifesciences Files IND Application To FDA For Phase 2 Study Of Ec-18 In Preventing ARDS Due To Covid-19 Pneumonia
Brief: Enzychem Lifesciences Initiates Phase 2 Study For Ec-18 In Preventing Acute Respiratory Distress Syndrome (Ards) Due To Novel Coronavirus Pneumonia
Brief: Enzychem Lifesciences Announces Filing Of U.S. Provisional Patent For Ec-18 For The Treatment Of Covid-19
Brief: Enzychem Lifesciences Announces Plans To Advance Clinical Trial In South Korea For EC-18 As A Potential Therapeutic For COVID-19 Infection
Brief: Enzychem Lifesciences - Agreement With Armed Forces Radiobiology Research Institute For Development Of Radiation Medical Countermeasure
Brief: Enzychem Lifesciences Issues New Shares Worth 26.5 Billion Won
Brief: Enzychem Lifesciences signs contract worth 81.54 bln won